Search

Your search keyword '"Altomare, G"' showing total 358 results
Start Over Author "Altomare, G"
358 results on '"Altomare, G"'

1. Design and expected performances of the large acceptance calorimeter for the HERD space mission

Author

Pacini, L., Adriani, O., Bai, Y. -L., Bao, T. -W., Berti, E., Bottai, S., Cao, W. -W., Casaus, J., Cui, X. -Z., D’Alessandro, R., Formato, V., Gao, J. -R., Li, R., Liu, X., Lorusso, L., Lyu, L. -W., Marin, J., Martinez, G., Pizzolotto, C., Qin, J. -J., Quan, Z., Shi, D. -L., Starodubtsev, O., Tang, Z. -C., Tiberio, A., Vagelli, V., Velasco, M. A., Wang, B., Wang, Hongmei, R. -J., Z. -G., Xu, M., Yang, Y., Zhang, L., Zheng, J. -K., Alemanno, F., Aloisio, R., Altomare, G., Ambrosi, G., An, Q., Antonelli, M., Azzarello, P., Bai, L., Bai, Y. L., Bao, T. W., Barbanera, M., Barbato, F. C. T., Bernardini, P., Berti, B., Bertucci, B., X. J., Bi, Bigongiari, G., Bongi, M., Bonvicini, V., Bordas, P., Bosch-Ramon, V., Brogi, P., Cadoux, F., Campana, D., Cao, W. W., Cao, Z., Catanzani, E., Cattaneo, P. W., Chang, J., Chang, Y. H., Chen, G. M., Chen, F., Cianetti, F., Comerma, A., Cortis, D., Cui, X. H., Cui, X. Z., Dai, C., Dai, Z. G., Gaetanoe, De, Mitri, De, Palma, De, Felice, Di, Giovanni, Di, Santo, Di, Venere, Di, Dong, L., Dong, J. N., Donvito, Y. W., Duranti, G., D’Urso, M., Evoli, D., Fang, C., Fariña, K., Favre, L., Feng, Y., Feng, C. Q., Feng, H., Feng, H. B., Finetti, Z. K., Formato, N., Frieden, V., Fusco, J. M., Gao, P., Gargano, J. R., Gascon-Fora, F., Gasparrini, D., Giglietto, D., Giovacchini, N., Gomez, F., Gong, S., Gou, K., Guida, Q. B., Guo, R., Guo, D. Y., Guo, J. H., Y. Q., He, H. H., Hu, H. B., Hu, J. Y., Hu, Hu, P., Huang, Y. M., Huang, G. S., Huang, J., Huang, W. H., Huang, X. T., Huang, Y. B., Ionica, Y. F., Jouvin, M., Kotenko, L., Kyratzis, A., Marra, La, Li, D., M. J., Li, Q. Y., Li, S. L., Li, Li, T., Li, X., Li, Z., Liang, Z. H., Liang, E. W., Liao, M. J., Licciulli, C. L., Lin, F., Liu, S. J., Liu, D., Liu, H. B., Liu, H., Liu, J. B., Liu, S. B., Liu, X. W., Loparco, Y. Q., Loporchio, F., Lu, S., Lyu, X., Lyu, J. G., Maestro, L. W., Mancini, E., Manera, E., Marin, R., Marrocchesi, J., Marsella, P. S., Marzullo, M., Mauricio, D., Mocchiutti, J., Morettini, G., Mori, G., Mussolin, L., Nicola, Mazziotta, Oliva, M., Orlandi, A., Osteria, D., Pacini, G., Panico, L., Pantalei, B., Papa, F. R., Papini, S., Paredes, P., Parenti, J. M., Pauluzzi, A., Pearce, M., Peng, M., Perfetto, W. X., Perrina, F., Perrotta, C., Pillera, G., Pizzolotto, R., Qiao, C., Qin, R., Quadrani, J. J., Quan, L., Rappoldi, Z., Raselli, A., Ren, G., Renno, X. X., Ribo, F., Rico, M., Rossella, J., Ryde, M., Sanmukh, F., Scotti, A., Serini, V., Shi, D., Shi, D. L., Silveri, Q. Q., Starodubtsev, L., Su, O., D. T., Su, Sukhonos, M., Suma, D., Sun, A., Sun, X. L., Surdo, Z. T., Tang, A., Tiberio, Z. C., Tykhonov, A., Vagelli, A., Vannuccini, V., Velasco, E., Walter, M., Wang, R., Wang, A. Q., Wang, J. C., Wang, J. M., Wang, J. J., Wang, L., Wang, M., Wang, R. J., Wang, S., Wang, X. Y., Wang, X. L., Wei, Z. G., Wei, D. M., J. J., Wu, B. B., Wu, Wu, J., L. B., Wu, Wu, X., Xin, X. F., Y. L., Xu, Yan, Z. Z., Yang, H. R., Yin, Y., P. F., Yu, Yuan, Y. W., Zampa, Q., Zampa, G., Zha, N., Zhang, M., Zhang, C., Zhang, F. Z., Zhang, L. F., Zhang, S. N., Zhang, Y., Zhao, Y. L., Zheng, Z. G., Zhou, J. K., Zhu, Y. L., Zhu, F. R., and K. J.

Subjects
Space experiments, Energy, Scintillating fiber, Performance, Monte Carlo methods, Measurements of, Space stations, Space missions, Cosmology, Cosmic rays, Intelligent systems, Scintillation counters, Silicon detectors, Charge detectors, Fiber trackers, Radiation detection, Read out systems, Calorimeters
Published
2022

2. The High Energy cosmic-Radiation Detector (HERD) Trigger System

Author

Velasco, M. A., Bao, T., Berti, E., Bonvicini, V., Casaus, J., Giovacchini, F., Liu, X., Marco, R., Marín, J., Martínez, G., Mori, N., Oliva, A., Pacini, L., Quan, Z., Tang, Z., Xu, M., Zampa, G., Zampa, N., Adriani, O., Alemanno, F., Aloisio, R., Altomare, G., Ambrosi, G., An, Q., Antonelli, M., Azzarello, P., Bai, L., Bai, Y. L., Bao, T. W., Barbanera, M., Barbato, F. C. T., Bernardini, B., Bertucci, B., X. J., Bi, Bigongiari, G., Bongi, M., Bordas, P., Bosch-Ramon, V., Bottai, S., Brogi, P., Cadoux, F., Campana, D., Cao, W. W., Cao, Z., Catanzani, E., Cattaneo, P. W., Chang, J., Chang, Y. H., Chen, G. M., Chen, F., Cianetti, F., Comerma, A., Cortis, D., Cui, X. H., Cui, X. Z., Dai, C., Dai, Z. G., D'Alessandro, R., Gaetanoe, De, Mitri, De, Palma, De, Felice, Di, Giovanni, Di, Santo, Di, Venere, Di, Dong, L., Dong, J. N., Donvito, Y. W., Duranti, G., D'Urso, M., Evoli, D., Fang, C., Fariña, K., Favre, L., Feng, Y., Feng, C. Q., Feng, H., Feng, H. B., Finetti, Z. K., Formato, N., Frieden, V., Fusco, J. M., Gao, P., Gargano, J. R., Gascon-Fora, F., Gasparrini, D., Giglietto, D., Gomez, N., Gong, S., Gou, K., Guida, Q. B., Guo, R., Guo, D. Y., Guo, J. H., Y. Q., He, H. H., Hu, H. B., Hu, J. Y., Hu, Hu, P., Huang, Y. M., Huang, G. S., Huang, J., Huang, W. H., Huang, X. T., Huang, Y. B., Ionica, Y. F., Jouvin, M., Kotenko, L., Kyratzis, A., Marra, La, Li, D., M. J., Li, Q. Y., Li, Li, R., S. L., Li, Li, T., Li, X., Li, Z., Liang, Z. H., Liang, E. W., Liao, M. J., Licciulli, C. L., Lin, F., Liu, S. J., Liu, D., Liu, H. B., Liu, H., Liu, J. B., Liu, S. B., Liu, X. W., Loparco, Y. Q., Loporchio, F., Lu, S., Lyu, X., Lyu, J. G., Maestro, L. W., Mancini, E., Manera, E., Marrocchesi, R., Marsella, P. S., Martinez, G., Marzullo, M., Mauricio, D., Mocchiutti, J., Morettini, G., Mussolin, L., Nicola, Mazziotta, Orlandi, M., Osteria, D., Panico, G., Pantalei, B., Papa, F. R., Papini, S., Paredes, P., Parenti, J. M., Pauluzzi, A., Pearce, M., Peng, M., Perfetto, W. X., Perrina, F., Perrotta, C., Pillera, G., Pizzolotto, R., Qiao, C., Qin, R., Quadrani, J. J., Rappoldi, L., Raselli, A., Ren, G., Renno, X. X., Ribo, F., Rico, M., Rossella, J., Ryde, M., Sanmukh, F., Scotti, A., Serini, V., Shi, D., Shi, D. L., Silveri, Q. Q., Starodubtsev, L., Su, O., D. T., Su, Sukhonos, M., Suma, D., Sun, A., Sun, X. L., Surdo, Z. T., Tang, A., Tiberio, Z. C., Tykhonov, A., Vagelli, A., Vannuccini, V., Velasco, E., Walter, M., Wang, R., Wang, A. Q., Wang, B., Wang, J. C., Wang, J. M., Wang, J. J., Wang, L., Wang, M., Wang, R. J., Wang, S., Wang, X. Y., Wang, X. L., Wei, Z. G., Wei, D. M., J. J., Wu, B. B., Wu, Wu, J., L. B., Wu, Wu, X., Xin, X. F., Y. L., Xu, Yan, Z. Z., Yang, H. R., Yin, Y., P. F., Yu, Yuan, Y. W., Zha, Q., Zhang, M., Zhang, C., Zhang, F. Z., Zhang, L., Zhang, L. F., Zhang, S. N., Zhang, Y., Zhao, Y. L., Zheng, Z. G., Zhou, J. K., Zhu, Y. L., Zhu, F. R., and K. J.

Subjects
Cosmology, Gamma rays, Intelligent systems, Monte Carlo methods, Space stations, Tellurium compounds, Topology, Dark matter, Electron spectrum, Energy, Fundamental physics, Measurements of, Plastic scintillator detector, Precise measurements, Radiation detection, Space-borne, Trigger systems, Cosmic rays
Published
2022

5. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry*

Author

Gisondi, P., Cazzaniga, S., Chimenti, S., Maccarone, M., Picardo, M., Girolomoni, G., Naldi, L., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnù, B., Spaziani, G., Cusano, F., Iannazzone, Saletta S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Grilli, Cilioni E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., di Luzio, Scotto G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., dʼAmico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., DʼOria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., González Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavò, S., Manfrè, C., Borgia, F., Guerra, Puglisi A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Mozzillo, R., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricò, M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M.G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvarà, M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., Amerio, P., De Simone, C., DʼAgostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigò, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalà, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Fornasa, Veller C., and Trevisan, G. P.

Published
2015
Full Text
View/download PDF

7. Increased frequency of activated CD8+ T cell effectors in patients with psoriatic arthritis

Author

Diani, M, Casciano, F, Marongiu, L, Longhi, M, Altomare, A, Pigatto, P, Secchiero, P, Gambari, R, Banfi, G, Manfredi, A, Altomare, G, Granucci, F, Reali, E, Diani M., Casciano F., Marongiu L., Longhi M., Altomare A., Pigatto P. D., Secchiero P., Gambari R., Banfi G., Manfredi A. A., Altomare G., Granucci F., Reali E., Diani, M, Casciano, F, Marongiu, L, Longhi, M, Altomare, A, Pigatto, P, Secchiero, P, Gambari, R, Banfi, G, Manfredi, A, Altomare, G, Granucci, F, Reali, E, Diani M., Casciano F., Marongiu L., Longhi M., Altomare A., Pigatto P. D., Secchiero P., Gambari R., Banfi G., Manfredi A. A., Altomare G., Granucci F., and Reali E.

Abstract

The aim of this study is to identify subsets of T cells differentially represented in the circulation of patients with psoriatic arthritis and to evaluate the possibility that they can recirculate between peripheral blood and the inflamed joints. We analyzed the phenotype and cytokine expression in circulating CD8+ and CD4+ T cells in 69 subjects: 28 with cutaneous psoriasis, 15 patients with psoriatic arthritis, and 26 healthy subjects. In the circulation, the percentage of each subset was compared among the groups and correlation was calculated with the serum concentration of C-reactive protein. To investigate the migration of T cells towards the inflamed joints, we performed a transwell migration assay towards patient serum and synovial fluid. In selected patients we analyzed in parallel T cells from peripheral blood and from synovial fluid. In the circulation, we found increased percentage of CD8+ CCR6+ T cell effectors expressing CD69 and of IL-17-producing T cells in patients with psoriatic arthritis. CD8+ effector/effector memory T cells showed increased migration towards synovial fluid. Finally, in synovial fluid we found accumulation of CXCR3+ CD8+ T cells and CD69+ cells. CD4+ T cells in the two compartments shared many similarities with CD8+ T cells. The results indicate a role for memory T cell effectors in systemic and joint manifestations of psoriatic arthritis.

Published
2019

17. Blood to skin recirculation of CD4+ memory T cells associates with cutaneous and systemic manifestations of psoriatic disease

Author

Diani, M, Galasso, M, Cozzi, C, Sgambelluri, F, Altomare, A, Cigni, C, Frigerio, E, Drago, L, Volinia, S, Granucci, F, Altomare, G, Reali, E, Diani M., Galasso M., Cozzi C., Sgambelluri F., Altomare A., Cigni C., Frigerio E., Drago L., Volinia S., Granucci F., Altomare G., Reali E., Diani, M, Galasso, M, Cozzi, C, Sgambelluri, F, Altomare, A, Cigni, C, Frigerio, E, Drago, L, Volinia, S, Granucci, F, Altomare, G, Reali, E, Diani M., Galasso M., Cozzi C., Sgambelluri F., Altomare A., Cigni C., Frigerio E., Drago L., Volinia S., Granucci F., Altomare G., and Reali E.

Abstract

Blood to skin recirculation could play a role in the pathogenesis of psoriasis. To investigate this possibility we dissected the phenotype of circulating T cells in psoriasis patients, calculated the correlation the clinical parameters of the disease and performed a parallel bioinformatics analysis of gene expression data in psoriatic skin. We found that circulating CCR6+ CD4+ TEM and TEFF cells significantly correlated with systemic inflammation. Conversely, the percentage of CXCR3+ CD4+ TEM cells negatively correlated with the severity of the cutaneous disease. Importantly CLA+ CD4+ TCM cells expressing CCR6+ or CCR4+ CXCR3+ negatively correlated with psoriasis severity suggesting recruitment to the skin compartment. This assumption was reinforced by gene expression data showing marked increase of CCR7 and CLA-encoding gene SELPLG expression in psoriatic skin and strong association of their expression. The data enlightens a role for CD4+ T cells trafficking between blood and skin in cutaneous and systemic manifestations of psoriasis.

Published
2017

19. Pruritus characteristics in a large Italian cohort of psoriatic patients

Author

Damiani, G., Cazzaniga, S., Conic, R. R. Z., Naldi, L., Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnu, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., Amico, Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D'Oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., Gonzalez Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo, S., Manfre, C., Borgia, F., Puglisi Guerra, A., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Arico, M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvara, M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D'Agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigo, M., De Felice, C., Gubinelli, E., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappala, L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Damiani G., Cazzaniga S., Conic R.R.Z., Naldi L., Griseta V., Miracapillo A., Azzini M., Mocci L., Michelini M., Offidani A., Bernardini L., Campanati A., Ricotti G., Giacchetti A., Norat M., Gualco F., Castelli A., Cuccia A., Diana A., Roncarolo G., Belli M.A., Baldassarre M.A., Santoro G., Vena G.A., Lo Console F., Filotico R., Mastrandrea V., Brunetti B., Musumeci F., Carrabba E., Dal Mas P., Annicchiarico F., Benvegnu B., Spaziani G., Cusano F., Saletta Iannazzone S., Galluccio A., Pezza M., Marchesi L., Imberti G., Reseghetti A., Barbera C., Reggiani M., Lanzoni A., Patrizi A., Bardazzi F., Antonucci A., De Tommaso S., Wallnofer W., Ingannamorte F., Calzavara-Pinton P., Iannazzi S., Zane C., Capezzera R., Bassisi S., Rossi M.T., Altamura V., Vigl W., Nobile C., Aste N., Murgia S., Mugheddu C., Scuderi G., Baglieri F., Di Dio C., Cilioni Grilli E., Mastronardi C., Agnusdei C.P., Antrilli A., Aulisa L., Raimondo U., Scotto di Luzio G., Battarra V.C., Farro P., Plaitano R., Micali G., Musumeci M.L., Massimino D., Li Calzi M., La Greca S., Pettinato M., Sapienza G., Valenti G., De Giacomo P.F., Amico, Arcangeli F., Brunelli D., Ghetti E., Tulli A., Assi G., Amerio P., Laria G., Prestinari F., Spadafora S., Coppola M., Caresana G., Pezzarossa E., Felisi C., Donato L., Bertero M., Musso L., Pa lazzini S., Bruscino P., Agozzino U.C., Ottaviani M., Simoncini C., Virgili A., Osti F., Fabbri P., Volpi W., Caproni M., Lotti T., Prignano F., Buggiani G., Troiano M., Fenizi G., Altobella A., Amoruso A., Condello M., Goffredo A., Righini M.G., Alessandrini F., Satolli F., Zampetti M., Bertani E., Fossati S., Parodi A., Burlando M., Fiorucci C., Nigro A., Ghigliotti G., Massone L., Moise G.M., Serrai M., Cannata G., Campagnoli A.M., Daly M., Leporati C., Peila R., Filosa G., Bugatti L., Nicolini M., Nazzari G., Cestari R., Anastasio F., Larussa F.M., Pollice N., De Francesco F., Mazzocchetti G., Peris K., Fargnoli M.C., Di Cesare A., De Angelis L., Flati G., Biamonte A.S., Quarta G., Congedo M., Carcaterra A., Strippoli D., Fideli D., Marsili F., Celli M., Ceccarini M., Bachini L., D'Oria M., Schirripa V., De Filippi C., Martini P., Lapucci E., Mazzatenta C., Ghilardi A., Simonacci M., Bettacchi A., Gasco R., Zanca A., Battistini S., Dattola S., Vernaci R., Postorino F., Zampieri P.F., Padovan C., Gonzalez Intchaurraga M.A., Ladurner J., Guarneri B., Cannavo S., Manfre C., Borgia F., Puglisi Guerra A., Cattaneo A., Carrera C., Fracchiolla C., Mozzanica N., Prezzemolo L., Menni S., Lodi A., Martino P., Monti M., Mancini L., Sacrini F., Altomare G.F., Taglioni M., Lovati C., Mercuri S.R., Schiesari G., Giannetti A., Conti A., Lasagni C., Greco M., Ronsini G., Schianchi S., Fiorentini C., Niglietta S., Maglietta R., Padalino C., Crippa D., Pini M., Rossi E., Tosi D., Armas M., Ruocco V., Ayala F., Balato N., Gaudiello F., Cimmino G.F., Monfrecola G., Gallo L., Argenziano G., Fulgione E., Berruti G., Ceparano S., De Michele I., Giorgiano D., Leigheb G., Deledda S., Peserico A., Alaibac M., Piaserico S., Schiesari L., Dan G., Mattei I., Oro E., Arico M., Bongiorno M.R., Angileri R., Amato S., Todaro F., Milioto M., Bellastro R., Di Nuzzo S., De Panfilis G., Zanni M., Borroni G., Cananzi R., Brazzelli V., Lisi P., Stingeni L., Hansel K., Pierfelice V., Donelli S., Rastelli D., Gasperini M., Barachini P., Cecchi R., Bartoli L., Pavesi M., De Paola S., Corradin M.T., Ricciuti F., Piccirillo A., Viola L., Tataranni M., Mautone M.G., Lo Scocco G., Niccoli M.C., Brunasso Vernetti A.M.G., Gaddoni G., Resta F., Casadio M.C., Arcidiaco M.C., Luvara M.C., Albertini G., Di Lernia V., Guareschi E., Catrani S., Morri M., De Simone C., D'Agostino M., Agostino I., Calvieri S., Cantoresi F., Richetta A., Sorgi P., Carnevale C., Nicolucci F., Berardesca E., Ardigo M., De Felice C., Gubinelli E., Talamonti M., Camplone G., Cruciani G., Riccardi F., Barbati R., Zumiani G., Pagani W., Malagoli P.G., Pellicano R., Donadio D., Di Vito C., Cottoni F., Montesu M.A., Pirodda C., Addis G., Marongiu P., Farris A., Cacciapuoti M., Verrini A., Desirello G., Gnone M., Fimiani M., Pellegrino M., Castelli G., Zappala L., Sesana G., Ingordo V., Vozza E., Di Giuseppe D., Fasciocco D., Nespoli P., Papini M., Cicoletti M., Bernengo M.G., Ortoncelli M., Bonvicino A., Capella G., Doveil G.C., Forte M., Peroni A., Salomone B., Savoia P., Pippione M., Zichichi L., Frazzitta M., De Luca G., Tasin L., Simonetto D., Ros S., Trevisan G., Patamia M., Miertusova S., Patrone P., Frattasio A., Piccirillo F., La Spina S., Di Gaetano L., Marzocchi V., Motolese A., Venturi C., Gai F., Pasquinucci S., Bellazzi R.M., Silvestri T., Girolomoni G., Gisondi P., Veller Fornasa C., and Trevisan G.P.

Subjects
Male, Cross-sectional study, Severity of Illness Index, Cohort Studies, 030207 dermatology & venereal diseases, 0302 clinical medicine, Risk Factors, education, itch, pruritus, psoriasis, pustular psoriasis, treatment, Adolescent, Adult, Cross-Sectional Studies, Educational Status, Facial Dermatoses, Female, Foot Dermatoses, Genitalia, Hand Dermatoses, Humans, Italy, Middle Aged, Pruritus, Psoriasis, Registries, Sex Factors, Young Adult, Epidemiology, Young adult, skin and connective tissue diseases, Settore MED/33 - MALATTIE APPARATO LOCOMOTORE, Infectious Diseases, 030220 oncology & carcinogenesis, Cohort, PRURITIS EPIDEMIOLOGY, Settore MED/35 - MALATTIE CUTANEE E VENEREE, Cohort study, medicine.medical_specialty, PSORIAS, Dermatology, Article, 03 medical and health sciences, Pharmacotherapy, Settore MED/35, Severity of illness, medicine, business.industry, medicine.disease, Pruritus,Itch sensation, business
Abstract

Background: Psoriasis (Ps) is a chronic systemic autoimmune disease associated with pruritus in 64–98% of patients. However, few modestly sized studies assess factors associated with psoriatic pruritus. Objective: To investigate factors associated with Ps pruritus intensity. Methods: Psoriasis patients 18years or older seen in one of 155 centres in Italy between September 2005 and 2009 were identified from the Italian PsoCare registry. Patients without cutaneous psoriasis and those with missed information on pruritus were excluded. Results: We identified 10802 patients, with a mean age 48.8±14.3years. Mild itch was present in 33.2% of patients, moderate in 34.4%, severe in 18.7% and very severe in 13.7%. Higher itch intensity was associated with female gender, lower educational attainment compared to university degree, pustular psoriasis, psoriasis on the head, face, palmoplantar areas, folds and genitalia, more severe disease, disease duration

Published
2019

21. Consensus on the management of patients with psoriatic arthritis in a dermatology setting

Author

Gisondi, P., Altomare, G., Ayala, F., Conti, A., Dapavo, P., De Simone, Clara, Foti, C., Idolazzi, L., Lubrano, E., Malara, G., Marchesoni, A., Olivieri, I., Parodi, A., Peris, Ketty, Piaserico, S., Salvarani, C., Scarpa, R., Girolomoni, G., De Simone, C. (ORCID:0000-0002-0898-0045), Peris, K. (ORCID:0000-0002-5237-0463), Gisondi, P., Altomare, G., Ayala, F., Conti, A., Dapavo, P., De Simone, Clara, Foti, C., Idolazzi, L., Lubrano, E., Malara, G., Marchesoni, A., Olivieri, I., Parodi, A., Peris, Ketty, Piaserico, S., Salvarani, C., Scarpa, R., Girolomoni, G., De Simone, C. (ORCID:0000-0002-0898-0045), and Peris, K. (ORCID:0000-0002-5237-0463)

Abstract

Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis (PsO). Early diagnosis and prompt therapeutic intervention are crucial for limiting PsA progression and prevention of disability. Dermatologists are in a privileged position to detect early PsA. The management of patients with PsA in the dermatology setting is widely variable. Objective: To provide practical recommendations for the management of patients with PsA in the dermatology setting including early diagnosis and treatment. Methods: A consensus document was written by an expert panel composed by dermatologists (n = 12) and rheumatologists (n = 6). Eleven highly relevant questions were selected and elaborated with answers/statements based on a narrative literature review. The resulting document was discussed in a face-to-face meeting adopting a nominal group technique to reach consensus (i.e. 100% agreement) using the Delphi method. Results: A consensus was achieved in defining the following: the clinical characteristics differentiating inflammatory and non-inflammatory signs and symptoms of joint disease; the most important differential diagnoses of PsA in clinical practice; the most useful screening questionnaires, serum laboratory tests and imaging techniques for the detection of early PsA; the criteria for dermatologist to refer patients with PsO to rheumatologist; the criteria for the diagnosis of PsA; the selection of the indices that the dermatologist could use for measuring the activity and severity of PsA in clinical practice; when systemic steroids and/or intra-articular steroid injections are indicated in the treatment of PsA. Finally, systemic treatments including synthetic and biologic disease-modifying antirheumatic drugs to be considered for the treatment of PsA have been reported. Conclusions: The implementations of these practical recommendations could be very helpful for the management of patients with PsA in the dermatology setting including earl

Published
2018

22. Biosimilar infliximab: An expert view

Author

Genazzani, A., Altomare, G., Balato, N., Cusano, F., Depità, O., Loconsole, F., Giuseppe MICALI, Piaserico, S., Girolomoni, G., Genazzani, A, Altomare, G, Balato, Nicola, Cusano, F, De Pità, O, Loconsole, F, Micali, G, Piaserico, S, and Girolomoni, G.

Subjects
Ankylosing, Arthritis, Biosimilar pharmaceuticals, Dermatology, Infliximab, Rheumatoid, Spondylitis, 2708, Antibodies, Monoclonal, Molecular Weight, Italy, Humans, spondylitis, ankylosing, Drug Approval
Abstract

CT-P13, a biosimilar of infliximab, was the first biosimilar monoclonal antibody to be approved in both the European Union and Korea. As a monoclonal antibody, CT-P13 is a large molecule with a high molecular weight, and as such it differs from other biosimilars currently in the market. The comparability exercise for CT-P13, therefore, requires special consideration, as it was the first demonstration of biosimilarity between a biosimilar monoclonal antibody and its originator. This paper summarizes current regulations on the approval of biosimilars, describes the evidence leading to the approval of CT-P13, and discusses the potential role of this molecule in the Italian scenario on the basis of the view of a group of experts.

Published
2015

23. Consensus on the management of patients with psoriatic arthritis in a dermatology setting

Author

Gisondi, P., primary, Altomare, G., additional, Ayala, F., additional, Conti, A., additional, Dapavo, P., additional, De Simone, C., additional, Foti, C., additional, Idolazzi, L., additional, Lubrano, E., additional, Malara, G., additional, Marchesoni, A., additional, Olivieri, I., additional, Parodi, A., additional, Peris, K., additional, Piaserico, S., additional, Salvarani, C., additional, Scarpa, R., additional, and Girolomoni, G., additional

Published
2018
Full Text
View/download PDF

24. Consensus on the use of cyclosporine in dermatological practice

Author

Altomare, G., Ayala, F., Bardazzi, F., Bellia, G., Chimenti, S., Colombo, D., Flori, M. L., Girolomoni, G., Giuseppe MICALI, Parodi, A., Peris, K., Vena, G. A., Altomare, G., Ayala, Fabio, Bardazzi, F., Bellia, G., Chimenti, S., Colombo, D., Flori, M. L., Girolomoni, G, Micali, G., Parodi Giusino, Ugo, Peris, K., and Vena, G. A.

Subjects
Psoriasi, skin diseases, cyclosporine, psoriasis, dermatitis, Medicine (all), Skin disease, Dermatiti, Atopic
Abstract

Cyclosporine A (CsA) efficacy and safety have been proven in various dermatoses both in adults and in children even as long-term treatment. Over the last 25 years, Italian dermatologists have gathered relevant experience about CsA treatment for psoriasis and atopic dermatitis. This paper has been developed by an Italian Consensus Conference and it is aimed at providing recommendations based on real-world clinical experience in adult patients, consistent with efficacy and safety data arising from the scientific literature. The paper is mainly focused on the analysis of the optimal therapeutic schemes for psoriasis and atopic dermatitis, in terms of doses and treatment duration, according to individual characteristics and to the severity of the disease. Moreover, it overviews ideal management, taking into account pharmacological interactions, influence of comorbidities, and the most common adverse events related to CsA treatment

Published
2014

25. The Italian Euromelanoma Day: evaluation of results and implications for future prevention campaigns

Author

BONGIORNO, Maria Rita, Suppa, M, Altomare, G, Cannavò, SP, Capizzi, R, Catricalà, C, Colombo, E, Fargnoli, MC, Fossati, B, Frascione, P, Lisi, P, Santini, M, Scalvenzi, M, Peris, K, Italian investigators for the Euromelanoma prevention campaign, Suppa, M, Altomare, G, Cannavò, Sp, Capizzi, R, Catricalà, C, Colombo, E, Fargnoli, Mc, Fossati, B, Frascione, P, Lisi, P, Santini, M, Scalvenzi, Massimiliano, Peris, K, Italian investigators for the Euromelanoma prevention, c. a. m. p. a. i. g. n., Bongiorno, MR, Cannavò, SP, Fargnoli, MC, Scalvenzi, M, and Italian investigators for the Euromelanoma prevention campaign.

Subjects
Male, Questionnaires, Pediatrics, Skin Neoplasms, Health Behavior, Surveys and Questionnaires, inglese, 80 and over, Settore MED/35 - Malattie Cutanee E Veneree, Mass Screening, Medicine, Skin cancer, Young adult, Child, Melanoma, Early Detection of Cancer, Aged, 80 and over, integumentary system, Incidence (epidemiology), Middle Aged, Day screening campaign, Predictive value, Europe, Italy, Child, Preschool, Sunlight, Female, Risk assessment, Cutaneous malignant melanoma, Adult, medicine.medical_specialty, Adolescent, Dermoscopy, Health Promotion, Dermatology, Risk Assessment, Young Adult, Humans, Preschool, Mass screening, Aged, business.industry, medicine.disease, Surgery, Melanoma detection, Anniversaries and Special Events, Health promotion, business, Program Evaluation
Abstract

Background Melanoma incidence/mortality is increasing worldwide. “Euromelanoma Day” is a pan-European campaign for skin cancer prevention. Results of the 2010 Euromelanoma Day in Italy are reported herein. Materials and methods A questionnaire was used to collect data on participants' characteristics and suspected skin cancers. Result A total of 1085 participants was screened (64.1% females, median age 44 years). Suspicion rate, detection rate, and positive predictive values for melanoma were 1.3, 0.28 and 21.4%, respectively. Poorly educated, ≥35 years old, pale-skinned males were at higher risk for skin cancer than highly educated

Published
2014

26. Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis

Author

Gisondi, P., primary, Altomare, G., additional, Ayala, F., additional, Bardazzi, F., additional, Bianchi, L., additional, Chiricozzi, A., additional, Costanzo, A., additional, Conti, A., additional, Dapavo, P., additional, De Simone, C., additional, Foti, C., additional, Naldi, L., additional, Offidani, A., additional, Parodi, A., additional, Piaserico, S., additional, Prignano, F., additional, Rongioletti, F., additional, Stingeni, L., additional, Talamonti, M., additional, and Girolomoni, G., additional

Published
2017
Full Text
View/download PDF

27. Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer

Author

Bidoli, P, Cortinovis, D, Colombo, I, Crippa, A, Cicchiello, F, Villa, F, Cazzaniga, M, Altomare, G, Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, Altomare G., Bidoli, P, Cortinovis, D, Colombo, I, Crippa, A, Cicchiello, F, Villa, F, Cazzaniga, M, Altomare, G, Bidoli P, Cortinovis DL, Colombo I, Crippa A, Cicchiello F, Villa F, Cazzaniga ME, and Altomare G.

Abstract

Introduction: Erlotinib is useful in advanced non-small cell lung cancer although compliance and efficacy are diminished by skin rash in a high proportion of patients, often necessitating dose reduction or drug withdrawal. No effective treatment for the rash is available. Methods: We carried out a preliminary investigation on isotretinoin and clindamycin. Among 56 advanced lung cancer patients treated with erlotinib, 31 (53%) developed rash. Seven (35%) of the 20 G2/G3 cases agreed to treatment with clindamycin (450 mg/d, days 1-10; 300 mg/d, days 11-20) plus isotretinoin (20 mg/d, days 11-20) after being informed of the experimental nature of the combination. Results: In 6 of 7 (86%) patients, the rash resolved (G1/G0) without dose reduction; in the other patient (G3), the erlotinib dose also had to be reduced. Median time to resolution was 14 days (range 7-20 days). No rash-treatment adverse events occurred during 20 days of administration. Conclusions: Isotretinoin plus clindamycin promises to be the first effective treatment for erlotinib rash and is being tested further

Published
2010

28. Incidence of psoriasis and association with comorbidities in Italy: A 5-year observational study from a national primary care database

Author

Vena, G, Altomare, G, Ayala, F, Berardesca, E, Calzavara-Pinton, P, Chimenti, S, Giannetti, A, Girolomoni, G, Lotti, T, Martini, P, Mazzaglia, G, Peserico, A, Guerra, A, Sini, G, Cassano, N, Cricelli, C, Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Mazzaglia G, Peserico A, Guerra AP, Sini G, Cassano N, Cricelli C, Vena, G, Altomare, G, Ayala, F, Berardesca, E, Calzavara-Pinton, P, Chimenti, S, Giannetti, A, Girolomoni, G, Lotti, T, Martini, P, Mazzaglia, G, Peserico, A, Guerra, A, Sini, G, Cassano, N, Cricelli, C, Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Mazzaglia G, Peserico A, Guerra AP, Sini G, Cassano N, and Cricelli C

Abstract

An observational study was conducted to estimate the incidence of psoriasis in Italy, as well as the utilization of healthcare resources and the association with selected comorbidities in psoriasis patients. The data source was the Health Search/Thales Database, containing computer-based patient records from over 900 primary care physicians (PCPs) throughout Italy. The study cohort comprised all adults receiving a first-ever diagnosis of psoriasis during the years 2001-2005. From a total sample of 511,532 individuals, the incidence of psoriasis was 2.30-3.21 cases per 1,000 person-years. Psoriatic arthritis was present in 8% of psoriasis patients. The comparison with matched controls showed that psoriasis patients were more likely to have comorbidities (e. g., chronic bronchitis, chronic ischemic heart disease, obesity and diabetes mellitus) and to undergo PCP visits and hospitalizations, and to refer for specialist visits. The use of non-steroidal anti-inflammatory drugs appeared to be significantly more prevalent in patients as compared to controls. Topical therapy with corticosteroids and non-steroidal preparations accounted for 45.3% and 47.2% of all cases, respectively. Only a minority of cases used systemic immunosuppressive drugs or acitretin. The incidence rate of psoriasis in our study was particularly high and might reflect an overestimation by PCPs. Our results show the association between psoriasis and multiple comorbidities.

Published
2010

29. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

Author

Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Costanzo, Rosa Maria Alba, Conti, A., Dapavo, P., De Simone, Clara, Foti, C., Naldi, L., Offidani, A., Parodi, A., Piaserico, S., Prignano, F., Rongioletti, F., Stingeni, L., Talamonti, M., Girolomoni, G., Chiricozzi, A. (ORCID:0000-0002-6739-0387), De Simone, C. (ORCID:0000-0002-0898-0045), Gisondi, P., Altomare, G., Ayala, F., Bardazzi, F., Bianchi, L., Chiricozzi, Andrea, Costanzo, Rosa Maria Alba, Conti, A., Dapavo, P., De Simone, Clara, Foti, C., Naldi, L., Offidani, A., Parodi, A., Piaserico, S., Prignano, F., Rongioletti, F., Stingeni, L., Talamonti, M., Girolomoni, G., Chiricozzi, A. (ORCID:0000-0002-6739-0387), and De Simone, C. (ORCID:0000-0002-0898-0045)

Abstract

Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Moreover, the different availability and reimbursability of drugs in each country justifies national guidelines. Expert consensus can provide helpful guidelines for optimizing patient care. A total of 20 dermatologists from different areas of Italy and with large experience in the treatment of psoriasis agreed to participate in the guidelines expert panel who aimed to reach consensus on the factors influencing psoriasis severity, the indications for systemic treatments, the parameters to be considered in the choice of treatment, and the factors to be considered in the choice of biological treatment. The recommendations for the use, screening and monitoring of systemic therapies were based on the 2015 S3 European Dermatology Forum/European Academy of Dermatology and Venereology psoriasis guidelines. Recommendations on the treatment of psoriasis in special patient populations were also agreed. The final document was discussed in a meeting moderated by a facilitator with participation of the entire group and adopting a nominal group technique to reach consensus. A statement was regarded as consented when agreement was achieved by at least 75% of the voting experts according to the Delphi procedure.

Published
2017

30. Health-related quality of life in psoriasis: an analysis of Psocare project patients

Author

Spandonaro F, Altomare G, Berardesca E, Calzavara Pinton P, Chimenti S, Girolomoni G, Peserico A, Guerra AP, Vena GA, Polistena B, AYALA, FABIO, Spandonaro, F, Altomare, G, Berardesca, E, Calzavara Pinton, P, Chimenti, S, Girolomoni, G, Peserico, A, Guerra, Ap, Vena, Ga, Polistena, B, and Ayala, Fabio

Subjects
Costs and cost analysis, Psoriasis, Quality of life
Published
2011

31. Psoriatic disease: concept and implications

Author

SCARPA, RAFFAELE, BALATO, NICOLA, Altomare G., Marchesoni A., Matucci Cerinic M, Lotti T, Olivieri I., Vena G. A., Salvarani G., Valesini G., Giannetti A., Scarpa, Raffaele, Altomare, G., Marchesoni, A., Balato, Nicola, Matucci Cerinic, M, Lotti, T, Olivieri, I., Vena, G. A., Salvarani, G., Valesini, G., and Giannetti, A.

Published
2010

32. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database

Author

Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Giannetti A, Girolomoni G, Lotti T, Martini P, Mazzaglia G, Peserico A, Guerra AP, Sini G, Cassano N, Cricelli C, G., Vena, G., Altomare, Ayala, Fabio, E., Berardesca, P., CALZAVARA PINTON, S., Chimenti, A., Giannetti, G:girolomoni, T., Lotti, P., Martini, G., Mazzaglia, A., Peserico, A., PUGLISI GUERRA, G., Sini, N., Cassano, C., Cricelli, Vena, G, Altomare, G, Ayala, F, Berardesca, E, Calzavara-Pinton, P, Chimenti, S, Giannetti, A, Girolomoni, G, Lotti, T, Martini, P, Mazzaglia, G, Peserico, A, Guerra, A, Sini, G, Cassano, N, and Cricelli, C

Subjects
Psoriasi, healthcare resources, Adult, Male, Databases, Factual, Primary Health Care, primary care database, Arthritis, Psoriatic, Comorbidity, Middle Aged, comorbidities, skin cancer, melanoma, basal-cell carcinoma, squamous-cell carcinoma, case–case–control, sun exposure, Italy, Healthcare resource, incidence, epidemiology, psoriasis, Humans, Psoriasis, Female, Comorbiditie, Aged
Abstract

An observational study was conducted to estimate the incidence of psoriasis in Italy, as well as the utilization of healthcare resources and the association with selected comorbidities in psoriasis patients. The data source was the Health Search/Thales Database, containing computer-based patient records from over 900 primary care physicians (PCPs) throughout Italy. The study cohort comprised all adults receiving a first-ever diagnosis of psoriasis during the years 2001-2005. From a total sample of 511,532 individuals, the incidence of psoriasis was 2.30-3.21 cases per 1,000 person-years. Psoriatic arthritis was present in 8% of psoriasis patients. The comparison with matched controls showed that psoriasis patients were more likely to have comorbidities (e. g., chronic bronchitis, chronic ischemic heart disease, obesity and diabetes mellitus) and to undergo PCP visits and hospitalizations, and to refer for specialist visits. The use of non-steroidal anti-inflammatory drugs appeared to be significantly more prevalent in patients as compared to controls. Topical therapy with corticosteroids and non-steroidal preparations accounted for 45.3% and 47.2% of all cases, respectively. Only a minority of cases used systemic immunosuppressive drugs or acitretin. The incidence rate of psoriasis in our study was particularly high and might reflect an overestimation by PCPs. Our results show the association between psoriasis and multiple comorbidities.

Published
2010

33. Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel

Author

Girolomoni, Giampiero, Altomare, G, Ayala, F, Berardesca, E, Calzavara Pinton, P, Chimenti, S, Martini, P, Peserico, A, Puglisi Guerra, A, Antonio Vena, G, on behalf on the Delphi working group, Girolomoni, Giampiero, Altomare, Gianfranco, Ayala, Fabio, Berardesca, Enzo, Calzavara Pinton, Piergiacomo, Chimenti, Sergio, Martini, Patrizia, Peserico, Andrea, Puglisi Guerra, Antonio, and Antonio Vena, Gino

Subjects
medicine.medical_specialty, Pathology, Special populations, Consensus, Discoid lupus erythematosus, Alternative medicine, Consensu, Dermatology, Etanercept, Psoriasis, Surveys and Questionnaires, medicine, Humans, Surveys and Questionnaire, survey, Severe psoriasis, computer.programming_language, Psoriasi, Biological Products, clinical recommendations, treatment choice, business.industry, medicine.disease, Biological Therapy, Family medicine, Biological Product, business, computer, Delphi, Clinical recommendation, Human
Abstract

In the management of moderate-to-severe psoriasis, increasingly complex clinical scenarios necessitate practical tools for appropriate biologic therapy selection in individual patients. An Italian Delphi consensus panel provided guidance on biologic use in selected clinical scenarios. Methods: Ten experts defined statements under consideration, which were distributed as an online survey to a dermatologist panel. Plenary discussions of contentious statements were held to achieve consensus. Results: The survey was sent to 30 clinicians. After plenary discussions, consensus was reached on all 20 statements on the following topics: special populations; infections; comorbidities; immunogenicity; extra-cutaneous involvement; pregnancy; and adherence. Three statements required further discussion in order to gain consensus: use of subcutaneous biologics in mild liver impairment (final 94% agreement), use of any biologic in discoid lupus erythematosus (final 100% disagreement), and use of etanercept in patients with history of hypersensitivity reactions to drugs and/or food (final 75% disagreement). Conclusions: This Delphi expert consensus on the use of biologics in psoriasis provides practical recommendations for dermatologists to use when choosing an appropriate biologic in challenging but common clinical scenarios. More data are required to clarify clinical differences of biologic drugs used to treat psoriasis. © 2014 Informa UK Ltd.

Published
2015

34. A role for CCR5+CD4 T cells in cutaneous psoriasis and for CD103+ CCR4+ CD8 Teff cells in the associated systemic inflammation

Author

Sgambelluri, F, Diani, M, Altomare, A, Frigerio, E, Drago, L, Granucci, F, Banfi, G, Altomare, G, Reali, E, GRANUCCI, FRANCESCA, BANFI, GIUSEPPE, REALI, EVA, Sgambelluri, F, Diani, M, Altomare, A, Frigerio, E, Drago, L, Granucci, F, Banfi, G, Altomare, G, Reali, E, GRANUCCI, FRANCESCA, BANFI, GIUSEPPE, and REALI, EVA

Abstract

Recent results have identified critical components of the T cell response involved in the initiation and amplification phases of psoriasis. However the link between T cell responses arising in the skin and the systemic inflammation associated with severe psoriasis is largely unknown. We hypothesized that specific subsets of memory T cells recirculating from the skin could play a role. We therefore dissected the circulating memory T cell compartment in patients by analyzing the TCM, TEM and Teff phenotype, the pattern of CCR4 and CCR5 chemokine receptor expression and the expression of the tissue homing molecule CD103. For each subset we calculated the correlation with the Psoriasis Area and Severity Index (PASI) and with the extent of systemic inflammation measured as serum level of the prototypic short pentraxin, C reactive protein (CRP). Validation was performed by comparison with gene expression data in psoriatic plaques. We found that circulating CD103+CCR4+CCR5+ and CCR4+CCR6- CD8+ Teff cells, were highly correlated with CRP levels as well as with the validated index PASI, reflecting a link between skin involvement and systemic inflammation in patients with severe psoriasis. In addition we observed a contraction of circulating CCR5+ T cells in psoriasis patients, with a highly significant inverse correlation between CCR5+CD4 T cells and the PASI score. Increased expression of CCR5 and CCL5 genes in psoriatic skin lesions was consistent with an accumulation of CCR5+ cells in psoriatic plaques indicating a role for CCR5/CCL5 axis in disease pathogenesis.

Published
2016

36. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Author

Piaserico, Stefano, Cazzaniga, Simone, Chimenti, Sergio, Giannetti, Alberto, Maccarone, Mara, Picardo, Mauro, Peserico, Andrea, Naldi, Luigi, Griseta, V., Miracapillo, A., Azzini, M., Mocci, L., Michelini, M., Offidani, A., Bernardini, L., Campanati, A., Ricotti, G., Giacchetti, A., Norat, M., Gualco, F., Castelli, A., Cuccia, A., Diana, A., Roncarolo, G., Belli, M. A., Baldassarre, M. A., Santoro, G., Vena, G. A., Lo Console, F., Filotico, R., Mastrandrea, V., Brunetti, B., Musumeci, F., Carrabba, E., Dal Mas, P., Annicchiarico, F., Benvegnã¹, B., Spaziani, G., Cusano, F., Saletta Iannazzone, S., Galluccio, A., Pezza, M., Marchesi, L., Imberti, G., Reseghetti, A., Barbera, C., Reggiani, M., Lanzoni, A., Patrizi, A., Bardazzi, F., Antonucci, A., De Tommaso, S., Balestri, R., Wallnofer, W., Ingannamorte, F., Calzavara-Pinton, P., Iannazzi, S., Zane, C., Capezzera, R., Bassisi, S., Rossi, M. T., Altamura, V., Vigl, W., Nobile, C., Aste, N., Murgia, S., Mugheddu, C., Scuderi, G., Baglieri, F., Di Dio, C., Cilioni Grilli, E., Mastronardi, C., Agnusdei, C. P., Antrilli, A., Aulisa, L., Raimondo, U., Scotto di Luzio, G., Battarra, V. C., Farro, P., Plaitano, R., Micali, G., Musumeci, M. L., Massimino, D., Li Calzi, M., La Greca, S., Pettinato, M., Sapienza, G., Valenti, G., De Giacomo, P. F., D’amico, D., Arcangeli, F., Brunelli, D., Ghetti, E., Tulli, A., Assi, G., Amerio, P., Laria, G., Prestinari, F., Spadafora, S., Coppola, M., Caresana, G., Pezzarossa, E., Domaneschi, E., Felisi, C., Donato, L., Bertero, M., Musso, L., Pa lazzini, S., Bruscino, P., Agozzino, U. C., Ottaviani, M., Simoncini, C., Virgili, A., Osti, F., Fabbri, P., Volpi, W., Caproni, M., Lotti, T., Prignano, F., Buggiani, G., Troiano, M., Fenizi, G., Altobella, A., Amoruso, A., Condello, M., Goffredo, A., Righini, M. G., Alessandrini, F., Satolli, F., Zampetti, M., Bertani, E., Fossati, S., Parodi, A., Burlando, M., Fiorucci, C., Nigro, A., Ghigliotti, G., Massone, L., Moise, G. M., Serrai, M., Cannata, G., Campagnoli, A. M., Daly, M., Leporati, C., Peila, R., Filosa, G., Bugatti, L., Nicolini, M., Nazzari, G., Cestari, R., Anastasio, F., Larussa, F. M., Pollice, N., De Francesco, F., Mazzocchetti, G., Peris, K., Fargnoli, M. C., Di Cesare, A., De Angelis, L., Flati, G., Biamonte, A. S., Quarta, G., Congedo, M., Carcaterra, A., Strippoli, D., Fideli, D., Marsili, F., Celli, M., Ceccarini, M., Bachini, L., D’oria, M., Schirripa, V., De Filippi, C., Martini, P., Lapucci, E., Mazzatenta, C., Ghilardi, A., Simonacci, M., Bettacchi, A., Gasco, R., Zanca, A., Battistini, S., Dattola, S., Vernaci, R., Postorino, F., Zampieri, P. F., Padovan, C., González Intchaurraga, M. A., Ladurner, J., Guarneri, B., Cannavo', S., Manfrã, C., Borgia, F., Puglisi Guerra, A., Sedona, P., Cattaneo, A., Carrera, C., Fracchiolla, C., Mozzanica, N., Prezzemolo, L., Menni, S., Lodi, A., Martino, P., Monti, M., Mancini, L., Sacrini, F., Altomare, G. F., Taglioni, M., Lovati, C., Mercuri, S. R., Schiesari, G., Giannetti, A., Conti, A., Lasagni, C., Greco, M., Ronsini, G., Schianchi, S., Fiorentini, C., Niglietta, S., Maglietta, R., Padalino, C., Crippa, D., Pini, M., Rossi, E., Tosi, D., Armas, M., Ruocco, V., Ayala, F., Balato, N., Gaudiello, F., Cimmino, G. F., Monfrecola, G., Gallo, L., Argenziano, G., Fulgione, E., Berruti, G., Ceparano, S., De Michele, I., Giorgiano, D., Leigheb, G., Deledda, S., Peserico, A., Alaibac, M., Piaserico, S., Schiesari, L., Dan, G., Mattei, I., Oro, E., Aricã², M., Bongiorno, M. R., Angileri, R., Amato, S., Todaro, F., Milioto, M., Bellastro, R., Di Nuzzo, S., De Panfilis, G., Zanni, M., Borroni, G., Cananzi, R., Brazzelli, V., Lisi, P., Stingeni, L., Hansel, K., Pierfelice, V., Donelli, S., Rastelli, D., Gasperini, M., Barachini, P., Cecchi, R., Bartoli, L., Pavesi, M., De Paola, S., Corradin, M. T., Ricciuti, F., Piccirillo, A., Viola, L., Tataranni, M., Mautone, M. G., Lo Scocco, G., Niccoli, M. C., Brunasso Vernetti, A. M. G., Gaddoni, G., Resta, F., Casadio, M. C., Arcidiaco, M. C., Luvarã , M. C., Albertini, G., Di Lernia, V., Guareschi, E., Catrani, S., Morri, M., De Simone, C., D’agostino, M., Agostino, I., Calvieri, S., Cantoresi, F., Richetta, A., Sorgi, P., Carnevale, C., Nicolucci, F., Berardesca, E., Ardigã², M., De Felice, C., Gubinelli, E., Chimenti, S., Talamonti, M., Camplone, G., Cruciani, G., Riccardi, F., Barbati, R., Zumiani, G., Pagani, W., Malagoli, P. G., Pellicano, R., Donadio, D., Di Vito, C., Cottoni, F., Montesu, M. A., Pirodda, C., Addis, G., Marongiu, P., Farris, A., Cacciapuoti, M., Verrini, A., Desirello, G., Gnone, M., Fimiani, M., Pellegrino, M., Castelli, G., Zappalã , L., Sesana, G., Ingordo, V., Vozza, E., Di Giuseppe, D., Fasciocco, D., Nespoli, P., Papini, M., Cicoletti, M., Bernengo, M. G., Ortoncelli, M., Bonvicino, A., Capella, G., Doveil, G. C., Forte, M., Peroni, A., Salomone, B., Savoia, P., Pippione, M., Zichichi, L., Frazzitta, M., De Luca, G., Tasin, L., Simonetto, D., Ros, S., Trevisan, G., Patamia, M., Miertusova, S., Patrone, P., Frattasio, A., Piccirillo, F., La Spina, S., Di Gaetano, L., Marzocchi, V., Motolese, A., Venturi, C., Gai, F., Pasquinucci, S., Bellazzi, R. M., Silvestri, T., Girolomoni, G., Gisondi, P., Veller Fornasa, C., Trevisan, G. P., Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L, Psocare Study Group [.., Patrizi A, ], Piaserico, S, Cazzaniga, S, Chimenti, S, Giannetti, A, Maccarone, M, Picardo, M, Peserico, A, Naldi, L, Bongiorno, MR, Psocare Study Group, Monfrecola, Giuseppe, and Trevisan, Giusto

Subjects
Male, primary inefficacy, 75% improvement in the Psoriasis Area Severity Index score, PASI, PASI 75, Psoriasis Area Severity Index, TNF, biologics, efficacy, psoriasis, secondary loss of efficacy, switching, tumor necrosis factor, tumor necrosis factor-alfa inhibitors, Adult, Analysis of Variance, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Confidence Intervals, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Immunoglobulin G, Italy, Middle Aged, Multivariate Analysis, Predictive Value of Tests, Proportional Hazards Models, Psoriasis, Receptors, Tumor Necrosis Factor, Registries, Retrospective Studies, Risk Assessment, Severity of Illness Index, Treatment Outcome, Tumor Necrosis Factor-alpha, Young Adult, SWITHCES, psoriasis arthritis, pharmachological treatment, Etanercept, Monoclonal, Receptors, Settore MED/35 - Malattie Cutanee E Veneree, Humanized, Hazard ratio, Predictive value of tests, Drug, biologic, TNF-alpha, medicine.medical_specialty, Dermatology, Antibodies, Dose-Response Relationship, Settore MED/35, Internal medicine, Severity of illness, medicine, Adverse effect, psoriasi, Adalimumab, Infliximab, 2708, Proportional hazards model, business.industry, tumor necrosis factor-alfa inhibitor, Retrospective cohort study, medicine.disease, Confidence interval, Surgery, ANTI-TNFA, business
Abstract

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). Limitations: There was a small number of patients with complete follow-up data. Conclusion: PASI 75 response in patients who switched from one antie-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first antie-TNF-alfa.

Published
2014

37. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate:a randomized clinical trial (TRANSIT)

Author

Adamski, Z, Altomare, G, Aricò, M, Aste, N, Aubin, F, Augustin, M, Ayala, F, Bachelez, H, Baran, E, Barker, J, Belinchón, I, Berbis, P, Bernengo, Mg, Bessis, D, Beylot Barry, M, Bordas Orpinell, Fj, Burden, D, Bylaite, M, Cambazard, F, Carazo, S, Carrascosa, Jm, Carretero, G, Cerio, R, Chimenti, S, David, M, Duval Modeste, Ab, Eedy, D, Estebaranz, L, Filipe, P, Flytström, I, Fonseca, E, Gamanya, R, Ghislain, Pd, Giannetti, A, Girolomoni, G, Gospodinov, D, Griffiths, C, Grob, Jj, Guillet, G, Hernanz Hermosa, Jm, Hoffmann, M, Ioannidis, D, Jacobi, A, Jemec, G, Kadurina, M, Kaszuba, K, Katsambas, A, Kemeny, L, Kerkhof, P, Kragballe, K, Kuzmina, N, Lambert, K, Lázaro, P, Lotti, T, Luger, T, Matz, H, Modiano, P, Moessner, R, Moreno, D, Moreno Jímenez, Jc, Mørk, Nj, Mrowietz, U, Murphy, R, Nicolas, Jf, Nikkels, A, Oliveira, H, Ormerod, A, Ortonne, Jp, Parodi, A, Pasternack, R, Paul, C, Pec, J, PESERICO STECCHINI NEGRI DE SALVI, Andrea, Philipp, S, Piquet, L, Plantin, P, Puig, L, Reich, K, Reményik, E, Riedl, E, Röcken, M, Rustin, M, Saari, S, Saiag, P, Salmhofer, W, Schadendorf, D, Sebastian, M, Simaljakova, M, Simon, Jc, Spirén, A, Stalder, Jf, Stavrianeas, N, Sticherling, M, Ternowitz, T, Thaci, D, Thio, B, Uhlig, D, Valiukeviciene, S, Vanaclocha Sebastián, Fj, and Wozel, G.

Subjects
Male, medicine.medical_specialty, Dermatology, Antibodies, Monoclonal, Humanized, ustekinumab, methotrexate, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Psoriasis Area and Severity Index, law, Psoriasis, Internal medicine, Ustekinumab, Clinical endpoint, Medicine, Humans, 030212 general & internal medicine, Dose-Response Relationship, Drug, business.industry, Drug Substitution, digestive, oral, and skin physiology, Dermatology Life Quality Index, psoriasis, Middle Aged, medicine.disease, 3. Good health, Discontinuation, Surgery, Clinical trial, Treatment Outcome, Female, Dermatologic Agents, business, medicine.drug
Abstract

Background: limited data exist on transitioning patients with psoriasis from conventional systemic agents to biologics. Objectives: the TRANSIT study aimed to assess the efficacy and safety of two methotrexate-to-ustekinumab transition strategies. Methods: patients with moderate-to-severe psoriasis and inadequate methotrexate response were randomized 1 : 1 to receive ustekinumab with immediate (arm 1) or 4-week gradual (arm 2) methotrexate withdrawal. Patients weighing ≤ 100 kg or > 100 kg received ustekinumab 45 mg or 90 mg, respectively. The primary endpoint was the frequency of adverse events (AEs) at week 12. Secondary endpoints included additional safety, efficacy and patient-reported outcomes. We report the 12-week efficacy and safety results. Results: overall, 244 patients in arm 1 and 245 in arm 2 were randomized and received ustekinumab. Four patients per arm discontinued the trial by week 12. At week 12 in arms 1 and 2, respectively, 61% and 65% of patients experienced an AE, 2·9% and 2·4% had a serious AE, and 1·2% and 0·4% had an AE leading to ustekinumab discontinuation. In arms 1 and 2, respectively, median Psoriasis Area and Severity Index (PASI) score decreased from 15·2 and 15·4 at baseline to 2·9 and 2·8 at week 12; 58% and 62% of patients achieved a 75% reduction from baseline in PASI score (PASI 75) at week 12; median baseline Dermatology Life Quality Index fell from 8 and 9 at baseline to 1 (both arms) at week 16. Conclusions: ustekinumab was well tolerated and effective in patients who had an inadequate response to methotrexate. Both transition strategies resulted in similar week 12 safety and efficacy outcomes.

Published
2013
Full Text
View/download PDF

38. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

Author

Adamski, Z, Altomare, G, Aricò, M, Aste, N, Aubin, F, Augustin, M, Ayala, F, Bachelez, H, Baran, E, Barker, J, Belinchón, I, Berbis, P, Bernengo, Mg, Bessis, D, Beylot Barry, M, Bordas Orpinell, Fj, Burden, D, Bylaite, M, Cambazard, F, Carazo, S, Carrascosa, Jm, Carretero, G, Cerio, R, Chimenti, S, David, M, Duval Modeste, Ab, Eedy, D, Estebaranz, L, Filipe, P, Flytström, I, Fonseca, E, Gamanya, R, Ghislain, Pd, Giannetti, A, Girolomoni, G, Gospodinov, D, Griffiths, C, Grob, Jj, Guillet, G, Hernanz Hermosa, Jm, Hoffmann, M, Ioannidis, D, Jacobi, A, Jemec, G, Kadurina, M, Kaszuba, K, Katsambas, A, Kemeny, L, Kerkhof, P, Kragballe, K, Kuzmina, N, Lambert, K, Lázaro, P, Lotti, T, Luger, T, Matz, H, Modiano, P, Moessner, R, Moreno, D, Moreno Jímenez, Jc, Mørk, Nj, Mrowietz, U, Murphy, R, Nicolas, Jf, Nikkels, A, Oliveira, H, Ormerod, A, Ortonne, Jp, Parodi, A, Pasternack, R, Paul, C, Pec, J, PESERICO STECCHINI NEGRI DE SALVI, Andrea, Philipp, S, Piquet, L, Plantin, P, Puig, L, Reich, K, Reményik, E, Riedl, E, Röcken, M, Rustin, M, Saari, S, Saiag, P, Salmhofer, W, Schadendorf, D, Sebastian, M, Simaljakova, M, Simon, Jc, Spirén, A, Stalder, Jf, Stavrianeas, N, Sticherling, M, Ternowitz, T, Thaci, D, Thio, B, Uhlig, D, Valiukeviciene, S, Vanaclocha Sebastián, Fj, and Wozel, G.

Subjects
Male, medicine.medical_specialty, Population, Dermatology, Antibodies, Monoclonal, Humanized, law.invention, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Psoriasis Area and Severity Index, Internal medicine, Psoriasis, Ustekinumab, Clinical endpoint, medicine, Humans, 030212 general & internal medicine, Adverse effect, education, education.field_of_study, Dose-Response Relationship, Drug, business.industry, Drug Substitution, Middle Aged, medicine.disease, 3. Good health, Surgery, Regimen, Methotrexate, Treatment Outcome, Female, Dermatologic Agents, business, psoriasis, ustekinumab, methotrexate, medicine.drug
Abstract

Background: There are limited long-term, ‘real-world’ data on ustekinumab, or the effect of dose adjustment in suboptimal responders. Objectives: We describe 52-week data from TRANSIT, which initiated ustekinumab by licensed regimen and investigated exploratory dose adjustment. Methods: Patients with moderate-to-severe psoriasis and inadequate methotrexate response received ustekinumab, with immediate or gradual methotrexate withdrawal. Outcomes were similar between treatment arms at week 12 (primary endpoint), so week 52 data were pooled. Patients weighing ≤ 100 kg or > 100 kg were administered ustekinumab 45 or 90 mg, respectively. Patients weighing ≤ 100 kg without 75% improvement in Psoriasis Area and Severity Index (PASI 75) response at weeks 28 or 40 received a dose adjustment to 90 mg. The primary analysis used observed data. Results: Overall, 391 and 98 patients received ustekinumab 45 and 90 mg, respectively. Forty-four patients (9%) discontinued before week 52 (0·4% due to adverse events). At week 52 (in the overall population), 369 patients (83%) achieved a PASI score ≤ 5, and 341 patients (77%) achieved PASI 75; the median PASI score decreased from 15 at baseline to 1·8. At weeks 28 and 40, 84 and 31 patients, respectively, did not achieve PASI 75 and received a dose adjustment; by week 52, 35/82 (43%) and 15/31 (48%) of these patients, respectively, achieved PASI 75 (two discontinued between weeks 28 and 40). Conclusions: Ustekinumab showed sustained 1-year efficacy and was well tolerated when initially administered according to label. Adjusting the ustekinumab dose to 90 mg may result in clinically meaningful improvement in response in patients weighing ≤ 100 kg with suboptimal initial response.

Published
2013
Full Text
View/download PDF

47. Scalp disorders

Author

Di Maio, A., Abeni, D., Altomare, G., Berardesca, E., Pinton, P. C., De Simone, C., Giannetti, A., Gisondi, P., Lotti, T., Piaserico, S., Saraceno, R., and Vena, G. A.

Subjects
Scalp disorders, Calcipotriene plus betamethasone dipropionate gel, Psoriasis
Published
2010

48. Biological Drugs: Differing mechanisms of action

Author

Altomare, G, Arcangeli, F, Berardesca, E, Calzavara Pinton, P, Giannetti, A, Girolomoni, Giampiero, Lotti, T, Martini, P, Peserico, A, Simonacci, M, and Vena, Ga

Subjects
mechanisms of action, psoriasis, TNF blackees
Published
2009

Catalog

Books, media, physical & digital resources
See catalog results